Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanthanum carbonate to reduce intestinal phosphorus absorption and slow CKD progression in metabolic syndrome
2015-000619-42Phase 2Terminated
- Sponsor
- FIBICO
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanthanum carbonate in chronic kidney disease (CKD) and cardiometabolic risk (CMR), sponsored by FIBICO. Primary endpoint: Glomerular filtration rate by creatinine clearance. Started Mar 2015; status: terminated.
02
Drugs
lanthanum carbonate
03
Conditions
chronic kidney disease (CKD)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2015-000619-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000619-42.